Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLA1ER)

Drug Name

EC20 Drug Info

Synonyms

Technetium Tc-99m etarfolatide

Indication

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 3	[1]

Cross-matching ID

PubChem CID: 135428923
CAS Number: CAS 479578-27-3
TTD Drug ID: DMLA1ER

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Folate receptor alpha (FOLR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pyrimethamine	DM5X7VY	Malaria	1F40-1F45	Approved	[3]
Mirvetuximab soravtansine	DM5S4LX	Ovarian cancer	2C73	Approved	[4]
MK-8109	DM84LO5	Ovarian cancer	2C73	Phase 3	[5]
Farletuzumab	DMFLWX1	Non-small-cell lung cancer	2C25.Y	Phase 3	[6]
EC-145	DM0KVJC	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
FolateImmune	DMB9ADM	Renal cell carcinoma	2C90	Phase 2	[8]
Talotrexin	DM1AB4L	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[9]
BMS-753493	DMDQO0S	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[10]
EC0489	DM8RD4T	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
IMGN-853	DMR8OG2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Folate receptor alpha (FOLR1)	TTVC37M	FOLR1_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020691)
2	EP patent application no. 2822386, Folate receptor alpha binding ligands.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. Drug Des Devel Ther. 2015; 9: 4989-4996.
6	Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.Gynecol Oncol.2013 Jun;129(3):452-8.
7	Significance of Folate Receptor alpha and Thymidylate Synthase Protein Expression in Patients with Non-Small Cell Lung Cancer treated with Pemetrexed. J Thorac Oncol. 2013 January; 8(1): 19-30.
8	Responsiveness of the Effective Consumer Scale (EC-17). J Rheumatol. 2009 Sep;36(9):2087-91.
9	Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res. 2010; 2: 293-301.
10	A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):321-31.
11	National Cancer Institute Drug Dictionary (drug id 638649).
12	Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem. 2010 Jan;21(1):84-92.